Sep 23, 2026 04:02PM
Sep 23, 2026 04:01PM
Sep 17, 2026 04:15PM
Sep 17, 2026 04:15PM
Sep 8, 2026 08:30AM
Sep 4, 2026 06:00AM
Sep 3, 2026 07:30PM Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
Sep 1, 2026 07:30AM
Sep 1, 2026 07:30AM
Aug 24, 2026 08:01AM
Aug 24, 2026 08:01AM
Aug 24, 2026 08:00AM
Aug 5, 2026 08:00AM
Aug 3, 2026 04:01PM Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Jul 27, 2026 04:01PM
Jul 15, 2026 01:29PM
Jul 14, 2026 11:15AM
Jul 14, 2026 11:15AM
Jul 14, 2026 09:15AM
Jul 14, 2026 09:15AM
Jul 13, 2026 05:37PM FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
Jul 13, 2026 05:36PM
Jul 13, 2026 07:30AM
Jul 13, 2026 07:30AM
Jul 13, 2026 05:43AM
Jul 12, 2026 11:15AM
Jun 30, 2026 08:01AM
Jun 30, 2026 08:00AM Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Jun 29, 2026 06:59AM
Jun 29, 2026 06:59AM
Jun 22, 2026 09:05AM
Jun 22, 2026 08:30AM
Jun 4, 2026 07:30AM
Jun 4, 2026 07:30AM
May 28, 2026 04:01PM Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 21, 2026 06:00PM
May 21, 2026 06:00PM
May 14, 2026 07:16AM
May 14, 2026 06:59AM
May 14, 2026 06:59AM
May 8, 2026 02:30AM
May 8, 2026 02:30AM Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
May 7, 2026 04:01PM
Apr 30, 2026 04:01PM
Apr 8, 2026 04:01PM
Apr 7, 2026 04:01PM
Apr 7, 2026 04:01PM
Mar 31, 2026 06:59AM
Mar 31, 2026 06:59AM Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Mar 30, 2026 09:24AM

332,018 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All